Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Microba Life Sciences expects microbiome testing "to be routine"

Microba Life Sciences expects microbiome testing "to be routine"

Microba Life Sciences Ltd (ASX:MAP) CEO Dr Luke Reid speaks to Proactive's Thomas Warner about the company's work in developing gut microbiome testing services and associated therapeutics.

Reid says that microbiome testing will become "routine" during the coming years and that Microba is well-placed to take advantage of a potentially huge emerging market.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK